Prevalence & Suggested Testing for KRAS G12C Mutation in NSCLC




KRAS G12C is a type of KRAS mutation that occurs in 13% (1 in 8) of patients with NSCLC, yet too many patients go unidentified.1 Find the UNSEEN 13— consider testing for KRAS in eligible patients with NSCLC at diagnosis.2-4

Unseen 13

KRAS, Kirsten rat sarcoma; NSCLC, non-small cell lung cancer.

References: 1. Data on file, Amgen; 2020. 2. Lindeman NI, et al. J Thorac Oncol. 2018;13:323-358. 3. Kalemkerian GP, et al. J Clin Oncol. 2018;36:911-919. 4. Pennell NA, et al. Am Soc Clin Oncol Educ Book. 2019;39:531-542.